News from the FDA - Two new metastatic colorectal cancer treatments

Questions To Ask Your Health Care Provider

• Am I eligible for any of the newly approved metastatic colorectal cancer treatments?
• What are the risk or benefits of LONSURF or Fruzaqla?
• Are there any clinical trials that I should consider?

Open Clinical Trials

The following studies enroll people with advanced colorectal cancer:

• NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study evaluates the safety, effectiveness and tolerability of the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability-high (MSI-H) solid tumors that resisted prior PD-(L)1 therapy.
• NCT05253651: Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting. This study evaluates whether the drug Tukysa (tucatinib) combined with other cancer drugs is more effective than the standard-of-care treatment in people with HER2-positive colorectal cancer. 
• NCT02997228: Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study). This effort compares the effectiveness of combining  chemotherapy and immunotherapy with an immunotherapy drug alone.
• NCT04008030: Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer. This study compares the combination of immunotherapy agents nivolumab (Opdivo) plus ipilimumab (Yervoy) with nivolumab alone or chemotherapy alone in patients who have MSI-H or dMMR metastatic colorectal cancer .

Several other clinical trials for patients with colorectal cancer can be found here.